社区药房对接受额外监测药物患者的干预结果。

IF 2.1 Q3 PHARMACOLOGY & PHARMACY
Integrated Pharmacy Research and Practice Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI:10.2147/IPRP.S466129
Xabier Aizpurua-Arruti, Shalom Charlie I Benrimoj, Estibaliz Goyenechea, Arantxa Isla, Ainhoa Oñatibia-Astibia, Amaia Malet-Larrea, Miguel Ángel Gastelurrutia, Olatz Cuevas, Julen Rodríguez-Castejón, Saioa Domingo-Echaburu, María Ángeles Solinís, Montserrat García, Ana Del Pozo-Rodríguez
{"title":"社区药房对接受额外监测药物患者的干预结果。","authors":"Xabier Aizpurua-Arruti, Shalom Charlie I Benrimoj, Estibaliz Goyenechea, Arantxa Isla, Ainhoa Oñatibia-Astibia, Amaia Malet-Larrea, Miguel Ángel Gastelurrutia, Olatz Cuevas, Julen Rodríguez-Castejón, Saioa Domingo-Echaburu, María Ángeles Solinís, Montserrat García, Ana Del Pozo-Rodríguez","doi":"10.2147/IPRP.S466129","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Additional monitoring (AM) medicines include (i) medicines containing a new active substance; (ii) biological medicines; (iii) medicines with conditional approval or authorized in special situations; (iv) medicines which require further studies; (v) medicines that have specific requirements regarding the reporting of suspected adverse drug reactions (ADRs). When AM medicines are marketed, their most common ADRs are known, but safety information is limited because relatively rare ADRs are often not detected in clinical trials. Their AM status warrants real-world studies to identify other safety issues; however, such studies are lacking. Correct use and adherence to dosage regimen by patients are key factors for the evaluation of the safety and efficacy of medicines. The objective of this work was assessing the impact on safety, adherence, use and knowledge (U&K) about medicines and patient's quality of life (QOL), of community pharmacist (CP)-led interventions in a new service focused on AM medicines targeted at three prevalent chronic diseases: diabetes mellitus type 2, chronic obstructive pulmonary disease and cardiovascular disease.</p><p><strong>Patients and methods: </strong>A prospective interventional cohort study was conducted with a 6-month follow-up in 27 community pharmacies (145 patients). Safety, adherence to treatment, patient U&K and QOL were assessed at follow-up visits (months 0, 3 and 6).</p><p><strong>Results: </strong>The number of detected ADRs was 163 with 41 patients referred to the doctor. At baseline, 24.1% of the patients were non-adherent, mainly due to unintentional causes. After six months and 130 interventions by CPs on adherence, a significant reduction to lower than 5.8% was achieved. The inadequate U&K of medicines also decreased, from 47.6% to 7.9% after 182 interventions. Also, the patient's QOL improved.</p><p><strong>Conclusion: </strong>A new patient-centered pharmacy service provides some evidence on the important role of CP in assisting the proper and safe use of AM medicines, improving patient health outcomes.</p>","PeriodicalId":45655,"journal":{"name":"Integrated Pharmacy Research and Practice","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11296513/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outcomes of Community Pharmacy Interventions on Patients with Medicines Under Additional Monitoring.\",\"authors\":\"Xabier Aizpurua-Arruti, Shalom Charlie I Benrimoj, Estibaliz Goyenechea, Arantxa Isla, Ainhoa Oñatibia-Astibia, Amaia Malet-Larrea, Miguel Ángel Gastelurrutia, Olatz Cuevas, Julen Rodríguez-Castejón, Saioa Domingo-Echaburu, María Ángeles Solinís, Montserrat García, Ana Del Pozo-Rodríguez\",\"doi\":\"10.2147/IPRP.S466129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Additional monitoring (AM) medicines include (i) medicines containing a new active substance; (ii) biological medicines; (iii) medicines with conditional approval or authorized in special situations; (iv) medicines which require further studies; (v) medicines that have specific requirements regarding the reporting of suspected adverse drug reactions (ADRs). When AM medicines are marketed, their most common ADRs are known, but safety information is limited because relatively rare ADRs are often not detected in clinical trials. Their AM status warrants real-world studies to identify other safety issues; however, such studies are lacking. Correct use and adherence to dosage regimen by patients are key factors for the evaluation of the safety and efficacy of medicines. The objective of this work was assessing the impact on safety, adherence, use and knowledge (U&K) about medicines and patient's quality of life (QOL), of community pharmacist (CP)-led interventions in a new service focused on AM medicines targeted at three prevalent chronic diseases: diabetes mellitus type 2, chronic obstructive pulmonary disease and cardiovascular disease.</p><p><strong>Patients and methods: </strong>A prospective interventional cohort study was conducted with a 6-month follow-up in 27 community pharmacies (145 patients). Safety, adherence to treatment, patient U&K and QOL were assessed at follow-up visits (months 0, 3 and 6).</p><p><strong>Results: </strong>The number of detected ADRs was 163 with 41 patients referred to the doctor. At baseline, 24.1% of the patients were non-adherent, mainly due to unintentional causes. After six months and 130 interventions by CPs on adherence, a significant reduction to lower than 5.8% was achieved. The inadequate U&K of medicines also decreased, from 47.6% to 7.9% after 182 interventions. Also, the patient's QOL improved.</p><p><strong>Conclusion: </strong>A new patient-centered pharmacy service provides some evidence on the important role of CP in assisting the proper and safe use of AM medicines, improving patient health outcomes.</p>\",\"PeriodicalId\":45655,\"journal\":{\"name\":\"Integrated Pharmacy Research and Practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11296513/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Integrated Pharmacy Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/IPRP.S466129\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrated Pharmacy Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IPRP.S466129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:额外监测(AM)药品包括:(i) 含有新活性物质的药品;(ii) 生物药品;(iii) 有条件批准或在特殊情况下批准的药品;(iv) 需要进一步研究的药品;(v) 对报告可疑药品不良反应(ADRs)有特殊要求的药品。当 AM 药品上市时,其最常见的 ADR 已为人所知,但由于相对罕见的 ADR 常常在临床试验中未被发现,因此其安全性信息十分有限。由于 AM 药物的身份,有必要对其进行真实世界研究,以确定其他安全性问题;但目前还缺乏此类研究。患者正确使用和遵守用药方案是评价药物安全性和有效性的关键因素。这项工作的目的是评估由社区药剂师(CP)主导的干预措施对药品安全性、依从性、使用和知识(U&K)以及患者生活质量(QOL)的影响,这项新服务的重点是针对三种常见慢性病(2 型糖尿病、慢性阻塞性肺病和心血管疾病)的 AM 药品:对 27 家社区药房(145 名患者)进行了为期 6 个月的前瞻性干预队列研究。在随访期间(第 0、3 和 6 个月)评估了安全性、治疗依从性、患者 U&K 和 QOL:结果:发现的 ADR 为 163 例,其中 41 例患者被转诊。基线时,24.1%的患者未坚持用药,主要是由于无意原因造成的。经过 6 个月和 130 次由 CPs 对依从性进行干预后,依从性明显降低,低于 5.8%。在进行了 182 次干预后,用药不足率也从 47.6% 降至 7.9%。此外,患者的生活质量也得到了改善:一项新的以患者为中心的药学服务提供了一些证据,证明了 CP 在协助正确和安全使用 AM 药物、改善患者健康状况方面的重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Outcomes of Community Pharmacy Interventions on Patients with Medicines Under Additional Monitoring.

Purpose: Additional monitoring (AM) medicines include (i) medicines containing a new active substance; (ii) biological medicines; (iii) medicines with conditional approval or authorized in special situations; (iv) medicines which require further studies; (v) medicines that have specific requirements regarding the reporting of suspected adverse drug reactions (ADRs). When AM medicines are marketed, their most common ADRs are known, but safety information is limited because relatively rare ADRs are often not detected in clinical trials. Their AM status warrants real-world studies to identify other safety issues; however, such studies are lacking. Correct use and adherence to dosage regimen by patients are key factors for the evaluation of the safety and efficacy of medicines. The objective of this work was assessing the impact on safety, adherence, use and knowledge (U&K) about medicines and patient's quality of life (QOL), of community pharmacist (CP)-led interventions in a new service focused on AM medicines targeted at three prevalent chronic diseases: diabetes mellitus type 2, chronic obstructive pulmonary disease and cardiovascular disease.

Patients and methods: A prospective interventional cohort study was conducted with a 6-month follow-up in 27 community pharmacies (145 patients). Safety, adherence to treatment, patient U&K and QOL were assessed at follow-up visits (months 0, 3 and 6).

Results: The number of detected ADRs was 163 with 41 patients referred to the doctor. At baseline, 24.1% of the patients were non-adherent, mainly due to unintentional causes. After six months and 130 interventions by CPs on adherence, a significant reduction to lower than 5.8% was achieved. The inadequate U&K of medicines also decreased, from 47.6% to 7.9% after 182 interventions. Also, the patient's QOL improved.

Conclusion: A new patient-centered pharmacy service provides some evidence on the important role of CP in assisting the proper and safe use of AM medicines, improving patient health outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
3.40%
发文量
29
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信